In particular, although one study showed a worse prognosis in patients with HER2-positive breast cancer, other studies showed an association between higher circulating eosinophil count and better prognosis in all breast cancer subtypes or response to neoadjuvant chemotherapy in HR-/TNBC patients. Here, ERBB2 is linked to breast carcinoma.